ArticleMedicine2026
Identification of allergic rhinitis-related genes and mediating immune cells based on cis-eQTL: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this study, we aimed to identify genes causally associated with allergic rhinitis (AR) by extracting cis-expression quantitative trait loci (cis-eQTL) as instrumental variables using the Mendelian randomization (MR) method, and further explore the role mechanisms of gene-related immune cells in AR. All genome-wide association study (GWAS) and eQTL data were from public databases. Genes causally associated with AR were screened by the summary-data-based Mendelian randomization (SMR) method to obtain Gene set 1. Predicted AR-related genes from 5 databases were combined and intersected with Gene set 1 to get Gene set 2. Genes in Gene set 2 with H4 posterior probability > .75 were selected through colocalization analysis to obtain Gene set 3. Then, 2-step 2-sample MR analysis was used to identify potential mediating immune cells. Gene set 1 had 29 genes. Gene set 2 contained 10 genes after intersection. Gene set 3 included TNFRSF18, HCP5, and CD44. MR mediation analysis showed TNFRSF18 could be a significant exposure, and CD3 on CD39+ activated Treg and CD4+ Treg could be mediators. TNFRSF18 negatively regulated AR and positively regulated the 2 immune cells, while immune cells negatively regulated AR. TNFRSF18, HCP5, and CD44 are significantly causally associated with the development of AR and may serve as drug targets. Among them, TNFRSF18 is more strongly supported. It may inhibit AR progression by upregulating CD3 on CD39+ activated Treg and CD4+ Treg, highlighting the role of these immune cells in the gene-mediated protection against AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.